{"id":"W4397007022","doi":"10.1016/j.esmoop.2024.103282","title":"261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Durvalumab; Medicine; Chemotherapy; Metastatic melanoma; Docetaxel; Internal medicine; Oncology; Radiology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001068627,0.001464053,0.001092511,0.0002982225,0.0003054162,0.001231223,0.000960067,0.001461496,0.007785014],"category_scores_gemma":[0.0006272792,0.0004974228,0.001288141,0.0003229256,0.0005509796,0.0005599665,0.0003094126,0.003314155,0.002134238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001137925,"about_ca_system_score_gemma":0.00151186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001928235,"about_ca_topic_score_gemma":0.006189657,"domain_scores_codex":[0.9997683,0.0001015746,0.000007765449,0.00003917255,0.00002307868,0.000060067],"domain_scores_gemma":[0.9995628,0.0000563545,0.00007117833,0.00002555116,0.00002943948,0.0002546603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7807297,0.05146333,0.004243779,0.001151112,0.001518788,0.0001945484,0.0002111762,0.002529135,0.03903661,0.0008549588,0.01737312,0.1006938],"study_design_scores_gemma":[0.6983008,0.2798491,0.007298968,0.00009663633,0.0005684369,0.0002578913,0.00006868565,0.001097624,0.003886232,0.0004634938,0.008083131,0.00002906772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9624801,0.005215635,0.00111227,0.00172014,0.0004809521,0.006841003,0.01169355,0.0003568574,0.01009947],"genre_scores_gemma":[0.9537655,0.004935533,0.002595387,0.004002995,0.0002461204,0.00485087,0.01412122,0.0001085399,0.01537373],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007785014,"threshold_uncertainty_score":0.02604347,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0240032643173013,"score_gpt":0.335595626129557,"score_spread":0.3115923618122557,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}